Connect with us


Rising Toll of Antibiotic-Resistant Infections Costs Thousands of Lives and Billions in Healthcare Dollars Annually




WASHINGTON–(BUSINESS WIRE)–The Partnership to Fight Infectious Diseases (PFID) has published new data, analyzes and projections to 2035 on the human and economic toll of antimicrobial resistance (AMR), specifically linked to hospital-acquired infections. The data shows that treating people who acquired AMR infections in healthcare settings resulted in $5.8 billion in direct medical care costs and an additional $7.2 billion in economic losses from premature deaths. PFID worked with GlobalData Plc on the analysis, which yielded both national and state sheets highlighting the impact of antimicrobial resistance, what is really at stake and policy opportunities, such as the Pasteur Lawto better address this growing public health emergency.

About 2.8 million antibiotic-resistant infections occur in the United States each year and more than 35,000 people die from them. In addition to healthcare-acquired infections that put some of the most vulnerable patients at risk, such as those battling cancer or other chronic illnesses, AMR also challenges infection prevention, which is critical to everyday procedures such as joint replacements and caesarean sections.

RAM is a threat to everyone, and the COVID-19 pandemic has exacerbated the problem. A report from the Centers for Disease Control and Prevention found that in 2020 alone, there was a 15% increase in hospital-associated AMR infections and deaths compared to the previous year.

Data from the PFID’s AMR analysis also shows that communities of color are at higher risk of hospital-acquired AMR-related infections and deaths. Black patients are 12% and Hispanic patients 24% more likely to die from nosocomial AMR infection compared to their white counterparts.

“The data in these fact sheets shows very clearly that something needs to be done, and it needs to be done now,” said Candace DeMatteis, PFID’s vice president of policy. “We must call loud and clear for change and demand that political decision-makers take action to pass the PASTEUR law. This would create a more sustainable environment for antimicrobial R&D and commercialization and ensure a strong pipeline for future treatments, which are desperately needed as we daily run out of options for effective infection prevention and control.

By sharing facts about AMR in every state, the PFID seeks to raise awareness of AMR and related issues and rally support across the United States around what can be done now to be better prepared. The PASTEUR law will respond to the challenges of the antimicrobial market and will encourage the development of essential drugs to fight against increasingly resistant bacteria.

This new research is part of PFID’s ongoing work to advance awareness of the growing problem of antimicrobial resistance and to spur action for policy changes that address the threat of antimicrobial resistance. antimicrobial resistance for global health. To learn more about the Partnership for Infectious Diseases, visit and follow us on Twitter @LePFID and LinkedIn.

The Partnership to Fight Infectious Diseases (PFID) is a group of patients, providers, community organizations, academic researchers, business and worker groups and infectious disease experts working to raise awareness of the threats posed by infectious diseases.